Helomics® Corporation announced today that the Company is a finalist in the Pittsburgh Technology Council’s annual Tech 50 Awards. read more
The next generation in Personalized Healthcare™
Personalized healthcare should be comprehensive, precise, predictive, but most importantly, personal.
We believe that each patient is unique, and their cancer treatment should be too.
Helomics' ongoing array of multiple products and technologies provide unique clinical value through a Comprehensive Tumor Profile.
peer reviewed publications and
abstracts on ChemoFx
gynecologic cancer specimens received for ChemoFx testing
physicians have sent for ChemoFx testing
unique sets of gynecologic cancer cell specimens in our Biorepository